Natural killer (NK) cells constitute an important component of the initial immunological response against transformed cells. However, chronic exposure to the tumor microenvironment can fundamentally alter the ability of NK cells to sufficiently control tumor progression. Thus, the adoptive transfer of healthy, functional NK cells as an interventional therapy has been an area of great interest for improving patient outcomes. Recent developments in the field have provided a better understanding of what makes the NK compartment effective against malignant cells. Moreover, there are now multiple potential sources of NK cell products for infusion as well as techniques to manipulate these cells to enhance their antitumor functions. This review explores the advantages and disadvantages of various sources of NK cells as well as prospective therapeutic enhancements to adoptively transferred NK cells.
N atural killer (NK) cells are a critical component of the innate immune response against malignant cells. At their discovery in the 1970s, they were identified by their ability to kill tumor cells without prior sensitization to tumor antigens. [1] [2] [3] [4] This is distinct from the mechanism by which T cells lyse tumor cells, which requires recognition of tumor antigens presented in the context of major histocompatibility class (MHC) I or II by a specific T-cell receptor. Because of the delay in priming and expansion of T cells bearing a particular tumor antigen-specific receptor, NK cells act as a first line of defense against newly transformed cells.
Because NK cells do not require prior exposure to or recognition of specific tumor antigens, their activity must be highly regulated to limit their responses against healthy tissue. Regulation of their activity occurs at 2 levels. The first level is through the expression of inhibitory receptors. 5 These germ-line-encoded receptors come in 3 main varieties: (1) killer immunoglobulin-like receptors (KIRs); (2) the c-type lectin, NKG2A/CD94; and (3) leukocyte immunoglobulin-like receptors. 6 The ligands for these various inhibitory receptors are the ubiquitously expressed MHC-I. When MHC-I molecules are ligated by NK cell-expressed inhibitory receptors, they provide an inhibitory signal to the NK cell that prevents it from becoming activated, blocking degranulation and cytokine production ( Fig. 1 ). This mechanism acts as a form of NK cell tolerance and protects healthy tissue from NK cell killing as healthy cells express normal levels of MHC-I molecules. Inhibitory receptor ligation with cognate MHC-I during NK cell development also serves as a mechanism by which NK cells are "educated" to respond to MHC-I-deficient cells. 7 However, this is not the only mechanism by which NK cell activity is regulated.
Natural killer cells express a complement of germ-lineencoded activation receptors that include the natural cytotoxicity receptors (e.g., NKp30, NKp44, NKp46, and NKp80, etc.), the c-type lectins, NKG2D and NKG2C/CD94, the SLAM family receptors (e.g., 2B4, NTB-A), and the low-affinity Fc receptor, CD16, among others. 8 While some of the ligands to these activation receptors are already present on healthy cells (e.g., CD48, NTB-A), the expression of many of them are induced upon cell stress. Under conditions where activation ligands are present on the cell surface, NK cell responses are dependent on the balance of inhibitory and activating signals. [9] [10] [11] When activation signals outweigh inhibitory ones, the NK cell can mediate a response against the target.
Natural killer cells kill tumor targets through a variety of mechanisms. First, they destroy tumor cells through receptormediated cytotoxicity. Natural killer cells express a variety of germ-line-encoded receptors such as the c-type lectin homodimer, NKG2D, which binds to stress induced ligands (e.g., ULBP's, MICA/MICB) typically expressed on tumor cells. 12, 13 Upon ligation, NK cells degranulate, releasing perforin and granzymes to induce target cell apoptosis. Natural killer cell degranulation can also be triggered though a process called antibody-dependent cell-mediated cytotoxicity (ADCC). 14 This process is dependent on the presence of tumor-specific antibodies bound to tumor surface antigens. The Fc portion of these antibodies is bound by the low-affinity Fc receptor, CD16, on NK cells and triggers degranulation. Natural killer cells can also mediate target cell killing through death receptor-mediated apoptosis. Natural killer cells can express the tumor necrosis factor family members FasL or tumor necrosis factor-related apoptosis inducing ligand (TRAIL), which can interact with their respective ligands Fas and TRAIL receptor expressed on tumor cells. [15] [16] [17] [18] While NK cells are capable of directly lysing tumor-transformed cells, they can also act as bridge between the innate and adaptive immune responses to enhance recognition and destruction of tumors by adaptive immune cells. This is achieved through the production and secretion of cytokines such as interferon γ (IFN-γ), which can restrict tumor angiogenesis as well as increase MHC-II expression on tumor cells and antigen-presenting cells, thereby enhancing adaptive immune responses. 19, 20 Despite the mechanisms by which NK cells can recognize and destroy tumor-transformed cells, over the course of tumor progression the malignant cells develop opposing mechanisms though which they subvert or alter immune responses, including those from NK cells. Evasion of the NK cell response by tumor cells is achieved through the down-regulation of adhesion molecules, activation ligands or costimulatory molecules for activation receptors, up-regulation of MHC-I molecules, or the shedding of soluble activation ligands. 21, 22 Tumor cells can also impact on NK cell function though the secretion of immunosuppressive factors such as interleukin 10 (IL-10), transforming growth factor β, or indoleamine 2,3-dioxygenase. 23 Natural killer cell defects observed in cancer patients include decreased activation receptor expression, reduced expression of intracellular signaling molecules, and overexpression of inhibitory receptors. 24 Consequently, these NK cells exhibit decreased cytotoxic and cytokine secreting function as well as decreased proliferation. 22 Considering that NK cells play an important role in the first line of defense against malignantly transformed cells, the use of NK cells in human cancer immunotherapy has been tested in patients at high risk or chemotherapy-refractory patients ( Table 1 ) and is described in this review. 
SOURCES OF NATURAL KILLER CELLS FOR ADOPTIVE TRANSFER

Autologous NK Cells
Initial studies in NK adoptive transfer aimed to improve the autologous NK cell antitumor responses through the use of cytokines to enhance NK cell function and proliferation. Stimulation of NK cells with cytokines such as IL-2, IL-12, IL-15, and IL-18 and type I IFNs results in highly activated NK cells with increased expression of adhesion molecules, cytokine-induced activating receptors (NKp44), perforin, granzymes, FasL, and TRAIL, as well as increased proliferation and cytokine production. [25] [26] [27] While up-regulation of these effector molecules results in heightened activity against malignant cells, limited clinical efficacy with a small proportion of sustained complete responses was observed in patients treated with the cytokine IL-2. Similar clinical outcomes were observed with patients who received adoptive transfer of autologous lymphokineactivated killer cells or more enriched NK cells stimulated ex vivo in combination IL-2 administration. 28, 29 More recently, we have learned that IL-2 therapy also results in activation and expansion of regulatory T cells that compete for IL-2 as well as directly inhibit NK cell function and can induce NK activation-induced cell death. [30] [31] [32] In addition, cytokine enhancement of autologous NK cell function may still be impaired by inhibition though tumorexpressed self-MHC or chronic immunosuppression by the host tumor. For these reasons, the use of haploidentical allogeneic NK cells from related donors was investigated for their efficacy in adoptive transfer.
Allogeneic NK Cells
Natural kill cells from healthy, related donors have the benefit of being educated in a nonimmunosuppressive environment and are therefore fully functional. Furthermore, the partial mismatch between the donor KIR repertoire and the recipient complement of MHC-I enables donor NK to respond to malignancies that retain normal MHC-I expression. 33, 34 Our team at the University of Minnesota performed the first trial using this approach in 2005. 35 This study included 43 patients with metastatic melanoma, renal cell carcinoma, or poor-prognosis acute myeloid leukemia (AML). Apheresis was performed on haploidentical-related donors to collect peripheral blood leukocytes, which were then depleted of CD3 + cells before an overnight stimulation with high-dose IL-2. Before NK cell infusion, patients were treated with 1 of 3 preparatory chemotherapy regimens: high cyclophosphamide and fludarabine (Hi-Cy [60 mg/kg Â 2 days]/ Flu [25 mg/m 2 Â 5 days]), low-dose cyclophosphamide (750 mg/m 2 ) and methylprednisone (1000 mg/m 2 ), or fludarabine alone (25 mg/m 2 Â 5 days). After infusion, patients received IL-2 infusions daily (1.75 Â 10 6 U/m 2 ) for 14 days. This was later modified to 6 higher doses of 10 Â 10 6 U over 2 weeks. Natural killer cell persistence and expansion were observed only in patients who received the Hi-Cy/Flu preparatory regimen, which is now defined by greater than 100 NK cells/μL of blood 12 to 16 days after infusion. There was a clear association between NK expansion and clinical responses, and we continue to use this surrogate endpoint. This trial resulted in 30% of patients with poor-prognosis AML undergoing complete remission. However, remission was not durable, and the patients who were not well enough to undergo definitive treatment with allogeneic transplantation ultimately had a relapse within a year. On a modified protocol, the addition of 400 cGy of total body irradiation was added to the Hi-Cy/Flu regimen in patients with refractory leukemia. The goal of this study was to further deplete host immune cells, thereby limiting the rejection of the transferred NK cells and creating space for donor NK homeostatic proliferation (Fig. 2 ). While this protocol required stem cell transplantation from the donor, it was done after the NK expansion endpoint was assessed. With this approach, approximately 50% of patients showed NK cell expansion. Furthermore, 66% of patients with NK cell expansion cleared their leukemia, suggesting that the adoptively transferred NK cells played a role in the antileukemia responses.
Our current approach at the University of Minnesota combines adoptively transferred NK cells, cytokines and lymphodepleting therapy (Hi-Cy/Flu) to achieve remission in patients with refractory AML. As in prior studies, we have used NK cell persistence and in vivo expansion as a surrogate metric to gauge clinical efficacy as there is a strong correlation between leukemia clearance and the number of donor-derived NK cells present 7 and 14 days after transfer. Although effective in some cases, this approach could be more robust, and several modifications to our current regimen are expected to improve clinical outcomes. Preclinical mouse models of regulatory T-cell (T-reg) depletion show enhanced FIGURE 2. Schema for adoptive transfer of haploidentical NK cells. Lymphocytes are apheresed from a healthy donor with a haploidentical HLA type to the recipient and depleted of B and T cells to minimize a graft-versus-host disease. Natural killer cells are then activated ex vivo with cytokines to enhance function prior to adoptive transfer. Before transplantation, the recipient undergoes a course of lymphodepleting chemotherapy to make space for the adoptively transferred cells. Activated donor NK cells are then infused, and the recipient is treated with IL-2 or IL-15 to encourage donor cell expansion.
responses to AML with antigen-specific T-cell therapies. We piloted this approach by adding an IL-2 immunotoxin (Ontak) to the lymphodepleting chemotherapy preparative regimen. While T-reg depletion was incomplete, we found NK expansion in 30% of patients, which again correlated with higher leukemia clearance than previously observed. 36 Because IL-2 induces expansion of T-reg cells, the use of IL-15 in place of IL-2 is an alternate approach to activate NK and T cells without T-reg stimulation, and this is currently being tested. In addition, selection of donors with favorable KIR genes of the B haplotype may add additional benefits, 37 but this requires formal clinical testing.
Induced Pluripotent Stem Cell-Derived NK Cells
While patient and related donors remain the primary sources of NK cells for adoptive transfer, stem cell-derived NK cells are an active focus of investigation. Differentiation of mature, functional NK cells can be achieved through the culture of bone marrow-or umbilical cord blood-derived CD34 + hematopoietic stem cells with IL-2/IL-15 along with allogeneic feeder cells and various growth factors such as stem cell factor and FLT-3L. 38, 39 These NK cells exhibit an immature phenotype, similar to CD56 bright NK cells, but show robust cytotoxicity and cytokine production. 40 However, some cells show expression of KIRs and CD16. Additional studies have tested whether induced pluripotent stem cells can be differentiated into hematopoietic stem cells and then into NK cells. 41 This method is feasible, and functionally, these NK cells seem to be more like the CD56 dim population as they mediate ADCC, as well as an effective antitumor response in in vivo xenogeneic mouse models. 42 Furthermore, induced pluripotent stem cellderived NK cells can serve as a renewable source of cells for therapy and can be genetically modified to express chimeric antigen receptors against specific tumor antigens to enhance their efficacy. 43 
NK Cell Lines
Malignant NK cell lines are another area of investigation for clinical use. The potential benefit of these cell lines is their inability to be inhibited by recipient human leukocyte antigen (HLA) because of low expression of KIRs or KIR-HLA mismatch in the recipient. 44 The cell lines NK-92, NKL, KHYG-1, and NKG have well-documented in vitro antitumor activity. 44 Recently, the NK-92 cell line has been approved by the Food and Drug Administration for clinical testing in patients with renal cell carcinoma and advanced malignant melanoma. 12, [45] [46] [47] It is currently the only NK cell line to date that has entered clinical trials; however, other established cell lines could be used in a similar manner. For instance, the KHYG-1 cell line exhibits greater cytotoxicity than the NK-92 cell line 48 and retains its enhanced cytolytic activity even when irradiated to inhibit proliferation. 49 Whether inhibited proliferation is a desirable trait remains to be determined, but will certainly enhance safety. The NKL cell line exhibits functional and proliferative ability similar to the CD56 dim CD16 + NK cell subset. 50 Their ability to mediate both ADCC and natural cytotoxicity makes them a prime candidate for use in adoptive immunotherapy. The main advantage to the use of NK cell lines is that they can be easily expanded and maintained in vitro under good manufacturing practice conditions for use in immunotherapy. Their function can also be enhanced through the use of cytokines. 45 Thus, adoptive transfer of NK cell lines may prove a useful alternative to the isolation and transfer of autologous or allogeneic NK cells for tumor immunotherapy.
Memory-Like NK Cells
Recently, a population of NK cells has been identified that expands in response to cytomegalovirus (CMV) infection 51 and has anti-CMVactivity as well as strong function against tumor targets. 52 Identified by their expression of the activation receptor NKG2C/CD94 and the maturation marker CD57, these NK cells have been shown to expand after CMV reactivation in transplant recipients. 53, 54 We have also shown that these cells are transplantable, persist at least a year after transplant in CMV-reactivated recipients, and are potent producers of IFN-γ when exposed to K562 cells or through CD16 signaling. 55, 56 The enhanced function of these cells makes them an area of interest for future use in tumor immunotherapy.
ENHANCEMENT OF ADOPTIVE TRANSFER THERAPIES
Although NK cell adoptive transfers show a great deal of promise in the clinic, complementary approaches or genetic manipulations geared at maximizing NK cell function, expansion, and persistence after transfer will be needed to move this form of immunotherapy forward. Interleukin 15 alone or as a superagonist with IL-15Rα 57 to achieve transpresentation holds great promise and may overcome the T-reg stimulatory effects of IL-2. Other cytokines such as IL-12 and IL-18 may induce priming of a memory-like NK cells with enhanced antitumor activity. 52, 58, 59 In instances where NK cell adoptive transfers are utilized as a means for maximizing ADCC, 2 strategies are being explored to improve this process, enhancing maintenance of the CD16 receptor and improving targeting through utilization of bispecific and trispecific molecules. Natural killer cell activation, through CD16 or other means, leads to a disintegrin and metalloproteinase 17 (ADAM-17) mediated clipping of the CD16 receptor, which is critical for mediation of ADCC. [60] [61] [62] [63] [64] To counter this matrix metalloproteinase-driven clipping and thereby enhance CD16 maintenance and ADCC, ADAM-17-specific inhibitors, as well as broader matrix metalloproteinase inhibitors, are being studied. 65, 66 In vitro success with the ADAM-17 inhibitor has led to an ongoing clinical trial at the University of Minnesota examining the combination of the ADAM-17 inhibitor and rituximab in patients with refractory lymphoma. Antibody-dependent cell-mediated cytotoxicity can be improved through utilization of bispecific and trispecific antibodies that bind directly to CD16, on the NK cell, and 1 or 2 tumor antigens, on the tumor cell. 67, 68 Direct binding to CD16, instead of CD16 binding to the Fc portion of an antibody bound to a tumor, provides stronger interactions and enhanced cytotoxicity. 69 Our group has recently focused its efforts on smaller, more versatile, bispecific and trispecific molecules termed BiKEs and TriKEs. [70] [71] [72] [73] Incorporation of ADAM-17 inhibitor and/or bispecific engagers after adoptive transfer will likely substantially enhance ADCC in this system.
Another way to use monoclonal antibodies in a post-adoptive transfer setting is to use them to block signaling pathways that inhibit NK cell function. The inhibitory KIRs are expressed in mature NK cells and block NK cell function upon encounter with cognate HLA class I ligands. Thus, efforts have been placed in the past to drive KIR-HLA mismatch in order to increase the graft-versusleukemia effect in the allogeneic setting, and a blocking antibody is being tested in the clinic to block inhibitory KIR signaling in the autologous setting. 68, [74] [75] [76] [77] Another inhibitory receptor that should be targeted for blockade in the posttransfer setting is NKG2A, because this receptor is up-regulated after transplant and adoptive transfer of NK cells and is thought to exert a significant amount of inhibition in the graft-versus-tumor setting. 78, 79 PD-1/PD-L1 axis blockade also warrants exploration in this setting because its expression is dynamically modulated after NK cell activation, and signaling in this pathway has been shown to reduce NK cell antitumor effect. 80 Genetic manipulation of NK cells has great potential for improving NK cell adoptive transfer therapies. Utilizing this strategy, NK cells being transferred could have enforced expression of genes coding for cytokines needed for expansion and survival (such as IL-2, IL-15, and IL-21), chemokine receptors needed for homing of the NK cell to the tumor, costimulatory receptors needed for maximization of function, and siRNAs and miRNAs targeting inhibitory NK cell receptors. 81 Genetic manipulation of NK cells is also being explored for expression of chimeric antigen receptors on the cells being transferred in, similar to approaches being taken with T cells, in order to maximize specific targeting of tumors and NK cell function after activation. 82 While the approach taken will likely depend on the type of cancer and stage at which the disease is detected, these exciting new methodologies are likely to revolutionize adoptive NK cells immunotherapies in the coming years.
SUMMARY
The prospects for successful and efficacious NK cell adoptive transfer therapies have increased only in recent years. As the use of allogeneic sibling derived NK cells continue to show great promise in cancer treatment, potential avenues now exist for tailormade or off-the-shelf NK products that could revolutionize NK adoptive transfer therapeutics. Furthermore, the development and administration of next-generation antibodies such as BiKEs and TriKEs can augment current therapies by targeting specific malignancies as well as enhancing the longevity and function of adoptively transferred NK cells.
